Roivant Sciences Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Roivant Sciences Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH2350980D
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Roivant Sciences Ltd (Roivant Sciences) focuses on delivering biomedical research by developing and commercializing novel therapies across diverse therapeutic areas. The company's pipeline compounds portfolio includes intepirdine, nelotanserin, RVT-103 and RVT-104,relugolix, RVT-602, RVT-801, RVT-501, RVT-201, RVT-701 and RVT-702. Its pipeline compounds find application in various therapeutic areas such as oncology, rare diseases, alzheimer's disease, prostate cancer and farber disease, among others. Roivant Sciences pipeline spans various therapeutic areas through strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies, including Takeda, Eisai, Vertex, Arena Pharmaceuticals, GlaxoSmithKline, Arbutus Biopharma, Duke University and Cincinnati Children's Hospital Medical Center. The company has operational presence in the US, and Switzerland. Roivant Sciences is headquartered in Hamilton, Bermuda.

Roivant Sciences Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Roivant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Roivant to Acquire SB742457 from GlaxoSmithKline 10

Axovant Sciences Acquires Rights to RVT-101 from Glaxo Group and GlaxoSmithKline Intellectual 11

Partnerships 12

Roivant Sciences and Plexcera Therapeutics Form Joint Venture 12

Takeda Pharma Forms Joint Venture with Roivant Sciences 13

Myovant Sciences Enters into Option Agreement with Roivant Sciences 14

Roivant Sciences Enters into Research Collaboration Agreement with Cincinnati Children's Hospital Medical Center 15

Axovant Sciences Exercises its Option Agreement with Roivant Sciences 16

Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 17

Licensing Agreements 18

Axovant Sciences Enters into Licensing Agreement with Qaam Pharma 18

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 19

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 20

Roivant Sciences Enters into Licensing Agreement with Eisai 21

Equity Offering 22

Roivant Sciences Raises USD1.1 Billion in Equity Investment 22

Axovant Sciences Raises USD143.8 Million Public Offering of Shares 23

Myovant Sciences Completes IPO for USD217.5 Million 24

Axovant Sciences Raises USD362 Million in IPO 26

Roivant Sciences Ltd-Key Competitors 27

Roivant Sciences Ltd-Key Employees 28

Roivant Sciences Ltd-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Strategy And Business Planning 30

Jun 06, 2017: Roivant Sciences Launches Urovant to Develop Innovative Therapies in Urology 30

Jul 12, 2016: Roivant Sciences and Plexcera Therapeutics Announce the Formation of Enzyvant Sciences to Focus on the Treatment of Farber Disease 31

Jun 07, 2016: Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate Cancer 32

Corporate Communications 33

Oct 19, 2016: Patrick Machado Joins Board of Directors of Roivant Sciences 33

Government and Public Interest 34

Jul 25, 2016: Alzheimer's Experts Call For End To Under-Treatment Of Disease 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Figures

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Roivant Sciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Roivant Sciences Ltd, Deals By Therapy Area, 2011 to YTD 2017 8

Roivant Sciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Roivant to Acquire SB742457 from GlaxoSmithKline 10

Axovant Sciences Acquires Rights to RVT-101 from Glaxo Group and GlaxoSmithKline Intellectual 11

Roivant Sciences and Plexcera Therapeutics Form Joint Venture 12

Takeda Pharma Forms Joint Venture with Roivant Sciences 13

Myovant Sciences Enters into Option Agreement with Roivant Sciences 14

Roivant Sciences Enters into Research Collaboration Agreement with Cincinnati Children's Hospital Medical Center 15

Axovant Sciences Exercises its Option Agreement with Roivant Sciences 16

Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 17

Axovant Sciences Enters into Licensing Agreement with Qaam Pharma 18

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 19

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 20

Roivant Sciences Enters into Licensing Agreement with Eisai 21

Roivant Sciences Raises USD1.1 Billion in Equity Investment 22

Axovant Sciences Raises USD143.8 Million Public Offering of Shares 23

Myovant Sciences Completes IPO for USD217.5 Million 24

Axovant Sciences Raises USD362 Million in IPO 26

Roivant Sciences Ltd, Key Competitors 27

Roivant Sciences Ltd, Key Employees 28

Roivant Sciences Ltd, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Roivant Sciences Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16120
Site License
USD 500 INR 32240
Corporate User License
USD 750 INR 48360

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com